NCT03694691 Developing Viability Index for Machine Perfused Livers
| NCT ID | NCT03694691 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Liver Cirrhoses |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2018-10-01 |
| Primary Completion | 2028-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2018-10-01 with a primary completion date of 2028-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Machine perfusion technology is nearing the point of rescuing discarded liver grafts in the hope of proving them to be or improving them to the point of being transplantable. However, there are no validated metrics to determine transplantability after machine perfusion. This study involves collecting biopsies from transplanted livers before and after implantation to correlate metabolite and gene expression with post-transplant function. This data will help develop a viability index for machine perfused livers.
Eligibility Criteria
Inclusion Criteria: * Male or female 18-75 years of age. * Candidate for a deceased-donor liver allograft. Exclusion Criteria: * Seropositivity for HIV-1.
Contact & Investigator
Heidi Yeh, MD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT03694691 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Liver Cirrhoses. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03694691 currently recruiting?
Yes, NCT03694691 is actively recruiting participants. Contact the research team at hyeh@mgh.harvard.edu for enrollment information.
Where is the NCT03694691 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT03694691 clinical trial?
NCT03694691 is sponsored by Massachusetts General Hospital. The principal investigator is Heidi Yeh, MD at Massachusetts General Hospital. The trial plans to enroll 60 participants.